Genmab (GMAB) Stock Price, Quote, News & History | Benzinga

SPY778.57+0.60%QQQ751.38+0.51%BTC/USD83,787.36+1.04%DIA516.21+0.89%GLD384.50+1.55%TLT77.97+0.12%

Genmab AS (GMAB) Stock Price, Quote, News & History

GMABNASDAQ

Trade with Public

Trade with Public

$37.07

1.022.83%

Last update: Oct 9, 3:59 PM

$36.34

0.290.8%

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Ownership Compare Options Stock Report

Key Statistics

Open

$36.55

Close

$37.07

Volume / Avg.

2.22M / 2.83M

Day Range

$37.04 - $37.05

52 Wk Range

23.62 - 40.17

Market Cap

$22.50B

P/E Ratio

28.49

Dividend Yield

-

Exchange

NASDAQ

RSI

61

Short Interest

0.98%

Days to Cover

2.09

Recent Genmab A/S News

Amazon To Rally Over 29%? Here Are 10 Top Analyst Forecasts For Thursday

Wall Street analysts updated ratings and price targets for top companies, including Robinhood, Westlake, Genmab, Levi Strauss, Generac, General Mills, and Amazon.

Avi Kapoor

Genmab/AbbVie Lymphoma Trial Meets Main Goal, Analyst Eyes Bigger Market Opportunity

Genmab reports positive Phase 3 EPCORE DLBCL-4 results in relapsed lymphoma; analyst points to label expansion and future growth opportunities.

Vandana Singh

Why Is ADC Therapeutics Stock Falling On Friday?

Discover why ADC Therapeutics (NYSE:ADCT) stock is tumbling on Friday as a prominent Wall Street analyst slashes targets due to serious trial safety signals.

Kaustubh Bagalkote

Why Is ADC Therapeutics Stock Falling Thursday?

ADC Therapeutics stock plunges premarket as LOTIS-3 trial shows elevated serious, Grade 5 adverse events despite meeting its primary endpoint.

Vandana Singh

Corbus Offers Upside Despite Post-FDA Update, Analyst Highlights Competitive Edge

Corbus reports FDA alignment on the CRB-701 path, as analysts flag upside tied to the head and neck cancer opportunity and obesity pipeline.

Vandana Singh

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

891.00M

Investing Cash Flow (TTM)

-5.63B

Financing Cash Flow (TTM)

4.96B

Free Cash Flow (TTM)

868.00M

Capital Expenditure (TTM)

-23.00M

Net Change in Cash (TTM)

214.00M

Analyst Trends and Forecast

2

Jul

1

Aug

1

Sep

4

Oct

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

3.5

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$26.32B

PE Ratio (TTM)

28.49

PE Ratio (FWD)

15.70

PEG Ratio (TTM)

4.54

PS Ratio (TTM)

5.44

PB Ratio (TTM)

3.72

Earnings Yield % (TTM)

3.51%

Earnings Yield % (FWD)

6.37%

EV / EBITDA (TTM)

20.08

Price / EBITDA (TTM)

17.71

Price / Free Cash Flow (TTM)

25.89

Book Value / Share

$9.69

Company Debt

Total Debt

$5.14B

LT Debt

$4.84B

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-$141.00M

Total Cash

$1.50B

Debt to Equity

0.89

Issuance of Debt (TTM)

-$141.00M

Repayment of Debt (TTM)

-$141.00M